Clinical
Trials Units Selected for Newly Restructured
HIV/AIDSResearch
Networks
NIH NEWS
National Institute
of Allergy and Infectious Diseases (National
Institutes of Health)
FOR IMMEDIATE RELEASE
Monday, March 12, 2007
Media Contact: Kathy Stover
(301) 402-1663
kstover@niaid.nih.gov
Clinical Trials Units Selected for Newly Restructured HIV/AIDS Research Networks
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced 60 U.S. and international institutions selected as HIV/AIDS Clinical Trials Units (CTUs) in a newly restructured system of six HIV/AIDS clinical research networks. NIAID expects to fund additional CTUs within the next several months, bringing the total to 73.
“These Clinical Trials Units will carry out the next generation of HIV/AIDS vaccine, prevention and treatment research,” says NIAID Director Anthony S. Fauci, M.D. “They will work with our clinical research networks in a flexible, collaborative and coordinated way to tackle the critical research questions that can help accelerate progress against the HIV/AIDS pandemic.” NIAID supports the world’s largest HIV/AIDS clinical research effort.
The CTU awards represent the second step of a two-part restructuring process of NIAID’s HIV/AIDS clinical trials networks. NIAID announced the clinical investigators and institutions responsible for leading the new networks in June 2006 (see http://www3.niaid.nih.gov/news/newsreleases/2006/leadership.htm).
Each
CTU is a member of one or more of the six NIAID HIV/AIDS networks: the AIDS
Clinical Trials Group, the HIV Prevention Trials Network, the HIV Vaccine
Trials Network, the International Maternal Pediatric Adolescent AIDS Clinical
Trials Network, the International Network for Strategic Initiatives in Global
HIV Trials, and the Microbicide Trials Network.
Return to HOME